[Effects of K18, a melphalan-human IgG conjugate, on hematologic neoplasms; phase II study experience].
Sakurai
M
M
Maseki
N
N
Hattori
M
M
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007951:Leukemia, Myeloid / Q000473:pathology / Q000628:therapy*; D008198:Lymph Nodes / Q000473:pathology; D008223:Lymphoma / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000473:pathology / Q000628:therapy*
D000970:Antineoplastic Agents